US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Direxion Daily S&P Biotech Bull 3x Shares

257.90

-7.8950-2.97%

Volume:147.06K

Turnover:38.65M

Market Cap:586.58M

PE:- -

High:271.77

Open:261.76

Low:257.33

Close:265.79

52wk High:341.93

52wk Low:93.20

Shares:2.27M

Float Shares:2.27M

Volume Ratio:2.29

T/O Rate:6.47%

Dividend:0.90

Dividend Rate:0.35%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Prime Medicine announces FDA clearance of IND application for PM647

Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM647 in Alpha-1 Antitrypsin Deficiency

Grail Shares Gain as FDA Panel Votes to Support Cancer Detection Test

Health Care Roundup: Market Talk

FDA Advisors Said it Should Approve the Grail Multicancer Blood Test. the Stock Rises Sharply.

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Arcturus Therapeutics (ARCT), Teladoc (TDOC) and Zimmer Biomet Holdings (ZBH)

Reliability Launches Healthcare-Focused Workplace Solutions Subsidiary

Analysts Offer Insights on Healthcare Companies: NanoViricides (NNVC) and Ionis Pharmaceuticals (IONS)

Pomdoctor Showcases Integrated ‘Hardware + AI + Payment’ Model to Redefine Digital Healthcare Infrastructure

TD ups Grail approval probability to 95% after panel vote

Sector Update: Healthcare

MT Newswires Live

Analysts Offer Insights on Healthcare Companies: Aethlon Medical (AEMD) and Kyverna Therapeutics, Inc. (KYTX)

Milestone Pharmaceuticals Enrolls First Canadian Study Participant in ReVeRA-301 Phase 3 Pivotal Trial Evaluating Etripamil Nasal Spray for AFib-RVR

Press Release: Satellos Announces FDA Clearance of IND Application for Forazapadin in Facioscapulohumeral Muscular Dystrophy (fshd) and a Partnership with FSHD Canada Foundation Providing Non-Dilutive Financing to Support Clinical Development

Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX), Oruka Therapeutics (ORKA) and Harmony Biosciences Holdings (HRMY)

aTyr Pharma Announces Alignment with FDA on Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis

Analysts Offer Insights on Healthcare Companies: Royalty Pharma (RPRX), Travere Therapeutics (TVTX) and Veeva Systems (VEEV)

FDA import ban puts Sheng Nuo Biotec's US business on red alert

Health Care Roundup: Market Talk

Sonic Healthcare Issues New Performance Rights Under Employee Incentive Scheme

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg1.tigeractivity.com/stock/LABU/news?page=11"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LABU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABU\",,,,,undefined,":{"symbol":"LABU","market":"US","secType":"STK","nameCN":"Direxion Daily S&P Biotech Bull 3x Shares","latestPrice":257.895,"timestamp":1790865980513,"preClose":265.79,"halted":0,"volume":147055,"delay":0,"changeRate":-0.029703901576432667,"floatShares":2274486,"shares":2274486,"eps":0,"marketStatus":"Trading","change":-7.895,"latestTime":"10-01 10:46:22 EDT","open":261.76,"high":271.7723,"low":257.33,"amount":38652559.7132,"amplitude":0.054337,"askPrice":260.54,"askSize":20,"bidPrice":259.37,"bidSize":20,"shortable":3,"etf":3,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1790884800000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":265.79,"sharesOutstanding":3074486,"nav":260.661,"aum":592869955.42,"dividendRate":0.003504,"bidAskSpread":0.003436,"preHourTrading":{"tag":"盘前","latestPrice":261.6,"preClose":265.79,"latestTime":"09:29 EDT","volume":2318,"amount":612617.1732800001,"timestamp":1790861345993,"change":-4.19,"changeRate":-0.015764,"amplitude":0.02976},"postHourTrading":{"tag":"盘后","latestPrice":266.5,"preClose":265.79,"latestTime":"19:59 EDT","volume":2105,"amount":559351.6497,"timestamp":1790812786487,"change":0.71,"changeRate":0.002671,"amplitude":0.007525},"volumeRatio":2.292673,"impliedVol":0.9451,"impliedVolPercentile":0.6255},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABU\",,,,,undefined,":{"symbol":"LABU","floatShares":2274486,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":2.292673,"shares":2274486,"dividePrice":0.9037,"high":271.7723,"amplitude":0.054337,"preClose":265.79,"low":257.33,"week52Low":93.2,"pbRate":"--","week52High":341.93,"institutionHeld":0,"latestPrice":257.895,"eps":0,"divideRate":0.003504,"volume":147055,"delay":0,"ttmEps":0,"open":261.76,"prevYearClose":159.39,"prevWeekClose":252.47,"prevMonthClose":265.79,"prevQuarterClose":265.79,"fiveDayClose":257.32,"twentyDayClose":311.81,"sixtyDayClose":317.19},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LABU\",params:#limit:5,,,undefined,":[{"date":"2025-09-23","symbol":"LABU","amount":0.10273,"announcedDate":"2025-09-22","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-23","defaultRemindTime":1758634200000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-30","payableDate":"2025-09-23","currency":"USD","dateTimestamp":1758600000000,"payDate":"2025-09-30"},{"date":"2025-06-24","symbol":"LABU","amount":0.21897,"announcedDate":"2025-06-23","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-24","defaultRemindTime":1750771800000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-07-01","payableDate":"2025-06-24","currency":"USD","dateTimestamp":1750737600000,"payDate":"2025-07-01"},{"date":"2025-03-25","symbol":"LABU","amount":0.10714,"announcedDate":"2025-03-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-25","defaultRemindTime":1742909400000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-01","payableDate":"2025-03-25","currency":"USD","dateTimestamp":1742875200000,"payDate":"2025-04-01"},{"date":"2024-06-25","symbol":"LABU","amount":0.15021,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-25","defaultRemindTime":1719322200000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-07-02","payableDate":"2024-06-25","currency":"USD","dateTimestamp":1719288000000,"payDate":"2024-07-02"},{"date":"2024-03-19","symbol":"LABU","amount":0.16064,"announcedDate":"2024-03-18","type":"dividend","market":"US","newRecordDate":"2024-03-20","defaultRemindTime":1710855000000,"name":"三倍做多标普生物-Direxion","recordDate":"2024-03-26","payableDate":"2024-03-20","currency":"USD","dateTimestamp":1710820800000,"payDate":"2024-03-26"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LABU\",market:\"US\",,,undefined,":[{"executeDate":"2018-06-19","recordDate":"2018-06-20","paymentDate":"2018-06-26","value":0.01932,"currency":"USD"},{"executeDate":"2018-09-25","recordDate":"2018-09-26","paymentDate":"2018-10-02","value":0.0954,"currency":"USD"},{"executeDate":"2018-12-27","recordDate":"2018-12-28","paymentDate":"2019-01-04","value":0.09621,"currency":"USD"},{"executeDate":"2019-03-19","recordDate":"2019-03-20","paymentDate":"2019-03-26","value":0.10973,"currency":"USD"},{"executeDate":"2019-06-25","recordDate":"2019-06-26","paymentDate":"2019-07-02","value":0.03745,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LABU\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LABU\",pageSize:20,pageCount:11,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2670629418","title":"Prime Medicine announces FDA clearance of IND application for PM647","url":"https://stock-news.laohu8.com/highlight/detail?id=2670629418","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670629418?lang=en_us&edition=fundamental","pubTime":"2026-09-25 04:05","pubTimestamp":1790280337,"startTime":"0","endTime":"0","summary":"Prime Medicine (PRME) announced that the FDA has cleared the company’s Investigational New Drug, or IND, application for PM647, an investigational ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/prime-medicine-announces-fda-clearance-of-ind-application-for-pm647-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/prime-medicine-announces-fda-clearance-of-ind-application-for-pm647-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","LABU","PRME","IND","BK4585","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670183504","title":"Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM647 in Alpha-1 Antitrypsin Deficiency","url":"https://stock-news.laohu8.com/highlight/detail?id=2670183504","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670183504?lang=en_us&edition=fundamental","pubTime":"2026-09-25 04:01","pubTimestamp":1790280060,"startTime":"0","endTime":"0","summary":"-- Clearance highlights continued execution, modularity and momentum across Prime Medicine’s liver franchise, building on recent regulatory clearances for PM577a -- -- Initial clinical data expected i","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/24/3368730/0/en/prime-medicine-announces-u-s-fda-clearance-of-investigational-new-drug-application-for-pm647-in-alpha-1-antitrypsin-deficiency.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","BK4588","IND","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670492599","title":"Grail Shares Gain as FDA Panel Votes to Support Cancer Detection Test","url":"https://stock-news.laohu8.com/highlight/detail?id=2670492599","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670492599?lang=en_us&edition=fundamental","pubTime":"2026-09-25 00:22","pubTimestamp":1790266920,"startTime":"0","endTime":"0","summary":"Shares of Grail rose after the healthcare company said a U.S. regulatory committee voted to approve its Galleri multi-cancer early detection test.The stock was up 5.6% at $114.59 as of midday Thursday. Shares have risen 34% this year.The company on Wednesday said a panel on the Food and Drug Administration's Medical Devices Advisory Committee voted to approve its premarket approval application for Galleri.The panel voted seven to two with one abstention that the test's benefits outweigh its risks, six to four that the test was effective, and unanimously in support of its safety.\"Today's vote reinforces the strength of Galleri's clinical evidence. We believe the panel's recommendations reaffirm a high evidence bar that GRAIL has set for a multi-cancer early detection test,\" Grail Chief Executive Josh Ofman said. \"GRAIL is committed to working with the FDA as it completes its review of Galleri, the first PMA submission for a multi-cancer early detection test.\"Galleri received a breakthro","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRAL","BK4585","BK4588","BK4139","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670513492","title":"Health Care Roundup: Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2670513492","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670513492?lang=en_us&edition=fundamental","pubTime":"2026-09-25 00:20","pubTimestamp":1790266800,"startTime":"0","endTime":"0","summary":"The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.1032 ET - UCB's portfolio offers growth potential into the next ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0868494617.USD","LU1804176565.USD","LU0417517546.SGD","LU1280957306.USD","UYG","LU0477156953.USD","LU0106831901.USD","IE00BBT3K403.USD","BK4553","LABU","LU2129689605.HKD","LU0098860793.USD","LU0149725797.USD","LU0170899867.USD","LU0683600562.USD","IE0034235188.USD","LU1880398471.USD","LU1894683264.USD","LU1291159041.SGD","FTXO","KBWB","LU0130103400.USD","LU0980610538.SGD","IYF","LU0320765489.SGD","LU0321505868.SGD","VFH","XLF","TCAF","IE00B19Z3B42.SGD","TFNS","LU0477156797.USD","LU2596442595.SGD","XLV","FNCL","LU1791807156.HKD","IE00BKVL7J92.USD","LU1496350502.SGD","LU1069347547.HKD","BAC","LU0256863811.USD","IE00B1BXHZ80.USD","IYG","LU1035773651.USD","LU2265009873.SGD","XBI","LU0234570918.USD","LU0648001328.SGD","IE00BLSP4239.USD","LU0234572021.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669499070","title":"FDA Advisors Said it Should Approve the Grail Multicancer Blood Test. the Stock Rises Sharply.","url":"https://stock-news.laohu8.com/highlight/detail?id=2669499070","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669499070?lang=en_us&edition=fundamental","pubTime":"2026-09-24 22:52","pubTimestamp":1790261520,"startTime":"0","endTime":"0","summary":"Mizuho's Bradley Bowers thinks the boost will be substantial. He wrote Tuesday that sales doubled in the launch years of other cancer-screening products-like colon cancer stool test Cologuard from the Exact Sciences unit of Abbott, or the colon cancer blood test Shield from Guardant Health.Galleri screens a person's blood sample for bits of DNA showing features typical of cancer cells. It tells you if it has found a general signal of cancer somewhere in your body-\"Cancer Signal Detected\"-and makes its best guess at the kind of tissue where the cancer is hiding.Clinical trials showed Galleri can detect cancers for which there is no standard screen, such as cancer of the ovary or pancreas. Grail's two big clinical trials showed that it rarely tells you that you have cancer when you don't. When you do have cancer, the test finds it on average about 50% of the 60% of the time.That is good performance, compared with other widely used screens, like the mammogram. Grail plans to tell customer","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FFOX","GNOM","IE00B2B36J28.USD","IE00B4R5TH58.HKD","BK4082","LU0889565916.HKD","LU2468319806.SGD","LU2112291526.USD","GNMX","LU0320765992.SGD","TMED","SGXZ41872573.SGD","IHI","LU1670627923.USD","LU1721429402.USD","LU1989763690.USD","BK4585","LU2324357040.USD","LU2237957811.SGD","LU0289739699.SGD","ABT","HELX","IE0002141913.USD","LU0320765489.SGD","LU0868494617.USD","GRAL","LU2089984988.USD","LU1691799644.USD","GH","LU0122379950.USD","PJP","SG9999004303.SGD","BK4196","LU1061106388.HKD","BK4551","BK4535","BK4568","BK4581","LU0211331839.USD","LFSC","LABU","BK4588","SG9999002232.USD","PTH","SG9999002224.SGD","BK4139","EKG","LU0882574055.USD","SGXZ23171101.USD","LU1721429741.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669499173","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Arcturus Therapeutics (ARCT), Teladoc (TDOC) and Zimmer Biomet Holdings (ZBH)","url":"https://stock-news.laohu8.com/highlight/detail?id=2669499173","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669499173?lang=en_us&edition=fundamental","pubTime":"2026-09-24 22:20","pubTimestamp":1790259612,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Arcturus Therapeutics (ARCT), Teladoc (TDOC) and Zimmer Biomet Ho...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-arcturus-therapeutics-arct-teladoc-tdoc-and-zimmer-biomet-holdings-zbh-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-arcturus-therapeutics-arct-teladoc-tdoc-and-zimmer-biomet-holdings-zbh-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4548","BK4504","LU1201861249.SGD","ZBH","LABU","LU0477156953.USD","LU0006061336.USD","LU0310800379.SGD","LU1267930490.SGD","LU1861558580.USD","LU1267930573.SGD","BK4167","XLV","TDOC","IE00B19Z3581.USD","IE00B7SZLL34.SGD","LU0130517989.USD","ARCT","LU0211327993.USD","BK4137","LU0648001328.SGD","LU0889566641.SGD","BK4566","LU0128526141.USD","LU0310799852.SGD","XBI","LU0029874061.USD","LU0211328371.USD","BK4567","IE00B19Z3B42.SGD","LU0128525929.USD","LU0792757196.USD","BK4585","LU0708994859.HKD","LU0130102774.USD","LU0029864427.USD","LU1861559042.SGD","LU1267930813.SGD","BK4139","BK4534","BK4588","BK4581","HCSG","BK4082","LU0980610538.SGD","IE0002270589.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669991774","title":"Reliability Launches Healthcare-Focused Workplace Solutions Subsidiary","url":"https://stock-news.laohu8.com/highlight/detail?id=2669991774","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669991774?lang=en_us&edition=fundamental","pubTime":"2026-09-24 22:18","pubTimestamp":1790259491,"startTime":"0","endTime":"0","summary":"Reliability ( ($RLBY) ) has issued an update. On September 24, 2026, Reliability Incorporated launched Reliability Workplace Solutions, LLC, a whol...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/reliability-launches-healthcare-focused-workplace-solutions-subsidiary?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/reliability-launches-healthcare-focused-workplace-solutions-subsidiary?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","LABU","BK4585","LU0029874061.USD","BK4581","XBI","LU0128526141.USD","HCSG","XLV","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669919495","title":"Analysts Offer Insights on Healthcare Companies: NanoViricides (NNVC) and Ionis Pharmaceuticals (IONS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2669919495","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669919495?lang=en_us&edition=fundamental","pubTime":"2026-09-24 21:30","pubTimestamp":1790256610,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on NanoViricides (NNVC) and Ionis Pharmaceuticals (IONS). NanoVirici...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-nanoviricides-nnvc-and-ionis-pharmaceuticals-ions-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-nanoviricides-nnvc-and-ionis-pharmaceuticals-ions-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","NNVC","LABU","BK4585","LU0029874061.USD","BK4568","IONS","BK4581","BK4139","LU0128526141.USD","XBI","HCSG","XLV","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669949594","title":"Pomdoctor Showcases Integrated ‘Hardware + AI + Payment’ Model to Redefine Digital Healthcare Infrastructure","url":"https://stock-news.laohu8.com/highlight/detail?id=2669949594","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669949594?lang=en_us&edition=fundamental","pubTime":"2026-09-24 21:27","pubTimestamp":1790256426,"startTime":"0","endTime":"0","summary":"PomDoctor Ltd. Unsponsored ADR ( ($POM) ) has shared an announcement. On September 24, 2026, Pomdoctor Limited highlighted its differentiated “hard...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/pomdoctor-showcases-integrated-hardware-ai-payment-model-to-redefine-digital-healthcare-infrastructure?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/pomdoctor-showcases-integrated-hardware-ai-payment-model-to-redefine-digital-healthcare-infrastructure?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HCSG","DIVL","LABU","CHAT","QTOC","AIPO","XLV","XBI","ARTY","DINT","BK4137","SAPH","ARMH","CVY","VTHR","AGIX","BK4585","AADR","LU0029874061.USD","APIE","BK4588","BK4581","LU0128526141.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669349596","title":"TD ups Grail approval probability to 95% after panel vote","url":"https://stock-news.laohu8.com/highlight/detail?id=2669349596","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669349596?lang=en_us&edition=fundamental","pubTime":"2026-09-24 21:20","pubTimestamp":1790256057,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Dan Brennan views the end result of the FDA panel meeting as solid for Grail (GRAL). The panel voted 7-2 with in favor of Galleri’...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/td-ups-grail-approval-probability-to-95-after-panel-vote-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/td-ups-grail-approval-probability-to-95-after-panel-vote-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4588","LABU","GRAL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669493651","title":"Sector Update: Healthcare","url":"https://stock-news.laohu8.com/highlight/detail?id=2669493651","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669493651?lang=en_us&edition=fundamental","pubTime":"2026-09-24 21:02","pubTimestamp":1790254979,"startTime":"0","endTime":"0","summary":"Healthcare stocks were flat to higher pre-bell Thursday, with the iShares Biotechnology ETF  inactive and the State Street Health Care Select Sector SPDR ETF  up 0.3%.ACADIA Pharmaceuticals  shares were down more than 4% in premarket activity after the company reported that its phase 2 RADIANT study of remlifanserin for Alzheimer's disease psychosis narrowly missed its primary endpoint.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ACAD","LU0029874061.USD","BK4137","LABU","BK4585","XLV","LU2065170008.USD","LU2065169927.USD","LU2065171402.SGD","BK4139","LU2065171311.SGD","LU0128526141.USD","BK4581","HCSG","IBB","BK4588","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669049359","title":"Analysts Offer Insights on Healthcare Companies: Aethlon Medical (AEMD) and Kyverna Therapeutics, Inc. (KYTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2669049359","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669049359?lang=en_us&edition=fundamental","pubTime":"2026-09-24 20:50","pubTimestamp":1790254216,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Aethlon Medical (AEMD) and Kyverna Therapeutics, I...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-aethlon-medical-aemd-and-kyverna-therapeutics-inc-kytx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-aethlon-medical-aemd-and-kyverna-therapeutics-inc-kytx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","KYTX","LU0128526141.USD","LU0029874061.USD","XLV","BK4585","BK4139","BK4588","BK4568","AEMD","BK4581","XBI","BK4583","BK4082","HCSG","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669934134","title":"Milestone Pharmaceuticals Enrolls First Canadian Study Participant in ReVeRA-301 Phase 3 Pivotal Trial Evaluating Etripamil Nasal Spray for AFib-RVR","url":"https://stock-news.laohu8.com/highlight/detail?id=2669934134","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669934134?lang=en_us&edition=fundamental","pubTime":"2026-09-24 20:00","pubTimestamp":1790251200,"startTime":"0","endTime":"0","summary":"Montreal Heart Institute Joins Multinational Study Evaluating a Self-Administered 70 mg Repeat-Dose Regimen of EtripamilMONTREAL and CHARLOTTE, N.C., Sept.  24, 2026 (GLOBE NEWSWIRE) -- Milestone Phar","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/24/3368250/0/en/milestone-pharmaceuticals-enrolls-first-canadian-study-participant-in-revera-301-phase-3-pivotal-trial-evaluating-etripamil-nasal-spray-for-afib-rvr.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1559883803.SGD","HYLG","BK4585","MEDX","ECG","GDOC","NVIB","LABU","VR","AV","IDNA","BK4588","LU0566484027.USD","BK4129"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669646251","title":"Press Release: Satellos Announces FDA Clearance of IND Application for Forazapadin in Facioscapulohumeral Muscular Dystrophy (fshd) and a Partnership with FSHD Canada Foundation Providing Non-Dilutive Financing to Support Clinical Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2669646251","media":"Dow Jones","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669646251?lang=en_us&edition=fundamental","pubTime":"2026-09-24 19:00","pubTimestamp":1790247600,"startTime":"0","endTime":"0","summary":"-- FDA clearance expands development of forazapadin into a second. degenerative muscle disease with significant unmet medical need. -- FSHD Canada Foundation to provide up to US$5 million in non-dilutive. financing toward the clinical development of forazapadin in FSHD. \"The collaboration between Satellos and the FSHD Canada Foundation provides non-dilutive capital to advance forazapadin's clinical development in FSHD. Under the agreement, the Foundation has agreed to contribute up to US$5 million in milestone payments over the next five quarters in exchange for a capped revenue-sharing interest in future FSHD-related proceeds. The funds are expected to support the IND-cleared Phase 2 randomized, double-blind, placebo-controlled proof-of-concept clinical study designed to evaluate","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","MSLE","BK4585","BK4139","IND","LABU","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669464161","title":"Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX), Oruka Therapeutics (ORKA) and Harmony Biosciences Holdings (HRMY)","url":"https://stock-news.laohu8.com/highlight/detail?id=2669464161","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669464161?lang=en_us&edition=fundamental","pubTime":"2026-09-24 18:30","pubTimestamp":1790245831,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Praxis Precision Medicines (PRAX), Oruka Therapeutic...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-praxis-precision-medicines-prax-oruka-therapeutics-orka-and-harmony-biosciences-holdings-hrmy-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-praxis-precision-medicines-prax-oruka-therapeutics-orka-and-harmony-biosciences-holdings-hrmy-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4137","ORKA","XBI","LU0109394709.USD","IE00B4R5TH58.HKD","IE00BJJMRZ35.SGD","HRMY","PRAX","BK4139","IE00B2B36J28.USD","LU0029874061.USD","HCSG","BK4588","IE0009355771.USD","BK4581","LU0889565916.HKD","LU0128526141.USD","IE00BJT1NW94.SGD","BK4007","LABU","LU0320765992.SGD","XLV","IBRN","IE00BFTCPJ56.SGD","IE0002141913.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669246156","title":"aTyr Pharma Announces Alignment with FDA on Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2669246156","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669246156?lang=en_us&edition=fundamental","pubTime":"2026-09-24 18:00","pubTimestamp":1790244000,"startTime":"0","endTime":"0","summary":"Global Phase 3 study will evaluate efzofitimod in patients with pulmonary sarcoidosis with restrictive lung disease utilizing FVC as primary endpoint. Company expects to initiate study-related activit","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/24/3368118/0/en/atyr-pharma-announces-alignment-with-fda-on-phase-3-study-of-efzofitimod-in-pulmonary-sarcoidosis.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","BK4588","FVC","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669770466","title":"Analysts Offer Insights on Healthcare Companies: Royalty Pharma (RPRX), Travere Therapeutics (TVTX) and Veeva Systems (VEEV)","url":"https://stock-news.laohu8.com/highlight/detail?id=2669770466","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669770466?lang=en_us&edition=fundamental","pubTime":"2026-09-24 17:30","pubTimestamp":1790242220,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Royalty Pharma (RPRX), Travere Therapeutics (TVTX) a...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-royalty-pharma-rprx-travere-therapeutics-tvtx-and-veeva-systems-veev-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-royalty-pharma-rprx-travere-therapeutics-tvtx-and-veeva-systems-veev-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IHE","PBE","BK4613","VEEV","LU1989764664.SGD","LU0106261372.USD","RPRX","LU0128526141.USD","LGHT","LU0029874061.USD","TVTX","BK4007","EKG","LABU","HCSG","LU0058720904.USD","BK4581","LU0170899867.USD","BK4534","BK4528","BK4585","LU0266013472.USD","BK4167","LFSC","XBI","LU0006306889.USD","BK4588","BK4137","LU0289739699.SGD","XLV","FFTY","BK4139","BK4504","LU1989764748.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193027650","title":"FDA import ban puts Sheng Nuo Biotec's US business on red alert","url":"https://stock-news.laohu8.com/highlight/detail?id=1193027650","media":"Deep News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1193027650?lang=en_us&edition=fundamental","pubTime":"2026-09-24 16:40","pubTimestamp":1790239239,"startTime":"0","endTime":"0","summary":"After its subsidiary Sheng Nuo Pharmaceutical underwent an on-site FDA inspection, peptide CDMO company Chengdu Sheng Nuo Biotec Co.,Ltd. (688117) received a Form 483 observation list and was...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688117","LABU","BK4588","BK4585","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669042468","title":"Health Care Roundup: Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2669042468","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669042468?lang=en_us&edition=fundamental","pubTime":"2026-09-24 16:20","pubTimestamp":1790238000,"startTime":"0","endTime":"0","summary":"The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.0721 GMT - Hikma Pharmaceuticals' new chief financial officer is","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","XLV","XBI","BK4585","LABU","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669826468","title":"Sonic Healthcare Issues New Performance Rights Under Employee Incentive Scheme","url":"https://stock-news.laohu8.com/highlight/detail?id=2669826468","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669826468?lang=en_us&edition=fundamental","pubTime":"2026-09-24 15:48","pubTimestamp":1790236106,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Sonic Healthcare Limited ( ($AU:SHL) ). Sonic Healthcare Limited has notified the market of the issue of 72,014...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/sonic-healthcare-issues-new-performance-rights-under-employee-incentive-scheme?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/sonic-healthcare-issues-new-performance-rights-under-employee-incentive-scheme?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XLV","LABU","XBI","BK4585","BK4588","BK4581"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":20,"pageCount":11,"totalSize":384,"code":"91000000","status":"200"}]}}